19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Sichuan University
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
The Institute of Cancer Research
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Kyoto Prefectural University of Medicine
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Kyoto Prefectural University of Medicine
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Institute of Cancer Research
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Sapienza University of Rome
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
